Mesentech is attending JP Morgan Healthcare ConferenceJan 6-11, 2019San Francisco, CA USA
Please email firstname.lastname@example.org to request a meeting
WSGR invites Mesentech to present at Healthcare Investment ForumNovember 6-9, 2018Palo Alto, CA USA
Wilson Sonsini Goodrich & Rosati's Healthcare Investment Forum presents an opportunity for life sciences venture investment firms to connect with promising start-ups to discuss potential funding. WSGR is the premier provider of legal services to technology, life sciences, and growth enterprises worldwide.
European Patent #EP2576575B1 GrantedSept 5, 2018
“Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof” granted 2018-09-05 (Patent is owned by SFU and licensed exclusively to Mesentech Inc.)
Clinical note published by Mesentech KOLs Drs. Sheikh & GlogauerJuly 23, 2018
American Academy of Implant Dentistry publishes clinical note (The Challenge of Predictable Vertical Alveolar Ridge Augmentation for Dental Implant Site Development) summarizing original research by Drs. Sheikh and Glogauer who won first place at the poster competition held at the American Academy of Implant Dentistry (AAID) 66th Annual Conference in San Diego. Full AAID summer issue.
Patent for "C3" US20180170951A1 PublishedJune 21, 2018
Third conjugate anabolic molecule, "C3," structure published. Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof (Patent is owned by SFU and licensed exclusively to Mesentech Inc.)
42nd Angel ForumNovember 15, 2017Vancouver, Canada
Mesentech will be at the 42nd Angel Forum
1st Place finisher at American Association for Implant Dentistry 66th Annual Conference October 11-14, 2017San Diego, CA USA
Drs Sheikh and Glogauer won first place at 66th annual AAID conference in San Diego for poster describing original research using Mesentech's novel bone-anabolic conjugates
US Patent for "C1" US9650414B1 GrantedMay 16, 2017
US Patent #9650414 “New classes of EP4 conjugate compounds -II; Dual Function Bone-targeting Peptide linked Pro-drugs” granted 2017-05-16 (Patent is owned by SFU and licensed exclusively to Mesentech Inc.)
RESI Partnering ConferenceApril 4, 2017Toronto, Canada
Mesentech will be attending the RESI Partnering Conference being held at MaRS Innovation Centre
Biocom Global Life Science Partnering Conference 2017March 1-2 2017San Diego, USA
Mesentech was selected as one of only ten companies from across Canada to participate in the Biocom Global Life Science Partnering Conference 2017 in the Consulate of Canada’s attendance.
BIO Investor Forum 2016October 18-19, 2016San Francisco, USA
Mesentech will be presenting at the 2016 BIO Investor Forum